Citations

Showing 10 of 108104 citations.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
Qu, Xiaoyu , Braziel, Rita M., Passerini, Verena , Leonard, John P. , Smith, Sonali M. , Kridel, Robert , Press, Oliver W. , Weigert, Oliver , Friedberg, Jonathan W. , Fang, Min , Press, Oliver , Li, Hongli , Rimsza, Lisa M. , Hsi, Eric D. , Kridel, Robert , LeBlanc, Michael

Mayo Clinic

Blood | November 19, 2018 | Volume: 133 | Issue: 1 | Pages: 81-93

10.1182/blood-2018-07-865428 | PMID 30446494 Get It

Abstract Although recent advances in molecular genetics have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIPI score, the impact on treatment has been limited. We aimed to assess the prognostic significance of copy-number aberrations (CNAs) and copy-neutral loss of heterozygosity (cnLOH) identified by chromosome genomic-array testing (CGAT) at FL diagnosis using prospectively collected clinical trial specimens from 255 patients enrolled in the SWOG study S0016. The impact of genomic aberrations was assessed for early progression (progressed or died within 2 years after registration), progression-free survival (PFS), and overall survival (OS). We showed that increased genomic complexity (ie, the total number of aberration calls) was associated with poor outcome in FL. Certain chromosome arms were critical for clinical outcome. Prognostic CNAs/cnLOH were identified: whereas early progression was correlated with 2p gain (P = .007; odds ratio [OR] = 2.55 [1.29, 5.03]) and 2p cnLOH (P = .005; OR = 10.9 [2.08, 57.2]), 2p gain specifically encompassing VRK2 and FANCL predicted PFS (P = .01; hazard ratio = 1.80 [1.14, 2.68]) as well as OS (P = .005; 2.40 [1.30, 4.40]); CDKN2A/B (9p) deletion correlated with worse PFS (P = .004, 3.50 [1.51, 8.28]); whereas CREBBP (16p) (P < .001; 6.70 [2.52, 17.58]) and TP53 (17p) (P < .001; 3.90 [1.85, 8.31]) deletion predicted worse OS. An independent cohort from the m7-FLIPI study was explored, and the prognostic significance of aberration count, and TP53 and CDKN2A/B deletion were further validated. In conclusion, assessing genomic aberrations at FL diagnosis with CGAT improves risk stratification independent of known clinical parameters, and provides a framework for development of future rational targeted therapies.
Infant male with TARP syndrome: Review of clinical features, prognosis, and commonalities with previously reported patients
Kaeppler, Kathrine E., Stetson, Raymond C. , Lanpher, Brendan C. , Collura, Christopher A.

Mayo Clinic

American Journal of Medical Genetics Part A | November 19, 2018 | Volume: 176 | Issue: 12 | Pages: 2911-2914

10.1002/ajmg.a.40645 | PMID 30450804 Get It

TARP syndrome (talipes equinovarus, atrial septal defect, Robin sequence, and persistent left superior vena cava) is a rare X‐linked condition. As more patients are identified through genetic testing, it is increasingly clear that the original TARP acronym does not fully describe the complete phenotypic spectrum of this syndrome. The presented patient had genetically confirmed TARP syndrome and demonstrated new findings of hydronephrosis and hemodynamically significant hypertrophic obstructive cardiomyopathy. The patient also had physical findings common with previously reported individuals with TARP syndrome in the literature but not described by the TARP acronym. These features include central nervous system dysfunction, renal abnormalities, cardiac lesions other than atrial septal defect or persistent left superior vena cava, and distal limb defects other than talipes equinovarus. By adding to the known spectrum of the TARP phenotype, this report will aid clinicians as they care for patients with this rare condition.
Extension of the mutational and clinical spectrum of SOX2 related disorders: Description of six new cases and a novel association with suprasellar teratoma
Blackburn, Patrick R. , Chacón‐Camacho, Oscar F. , Ortiz‐González, Xilma R. , Reyes-Rosales, Mariana , López-Uriarte, Graciela Arelí , Zarei, Shabnam , Bhoj, Elizabeth , Pérez‐Solórzano, Sofía, Murphree, Marine I., Nava, Jessica, Cortés‐González, Vianney , Parisi, Joseph E. , Villanueva‐Mendoza, Cristina , Tirado‐Torres, Iris G., Klee, Eric W. , Pichurin, Pavel N. , Bhoj, Elizabeth J , Zenteno, Juan C , Vaubel, Rachael A. , Li, Dong

Mayo Clinic

American Journal of Medical Genetics Part A | November 19, 2018 | Volume: 176 | Issue: 12 | Pages: 2710-2719

10.1002/ajmg.a.40644 | PMID 30450772 Get It

SOX2 is a transcription factor that is essential for maintenance of pluripotency and has several conserved roles in early embryonic development. Heterozygous loss‐of‐function variants in SOX2 are identified in approximately 40% of all cases of bilateral anophthalmia/micropthalmia (A/M). Increasingly SOX2 mutation‐positive patients without major eye findings, but with a range of other developmental disorders including autism, mild to moderate intellectual disability with or without structural brain changes, esophageal atresia, urogenital anomalies, and endocrinopathy are being reported, suggesting that the clinical phenotype associated with SOX2 loss is much broader than previously appreciated. In this report we describe six new cases, four of which carry novel pathogenic SOX2 variants. Four cases presented with bilateral anophthalmia in addition to extraocular involvement. Another individual presented with only unilateral anophthalmia. One individual did not have any eye findings but presented with a suprasellar teratoma in infancy and was found to have the recurrent c.70del20 mutation in SOX2 (c.70_89del, p.Asn24Argfs*65). This is this first time this tumor type has been reported in the context of a de novo SOX2 mutation. Notably, individuals with hypothalamic hamartomas and slow‐growing hypothalamo‐pituitary tumors have been reported previously, but it is still unclear how SOX2 loss contributes to their formation.
Low income as a determinant of exercise capacity in COPD
Porta, Ana Sofia , Lam, Nyanjok, Novotny, Paul J. , Benzo, Roberto , Bernard, Gordon R. , Hoffman, Jeanne M. , Kaplan, Robert C. , Novotny, Paul, Lam, Nyanjok M

Mayo Clinic

Chronic Respiratory Disease | November 18, 2018 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/1479972318809491 | PMID 30449156 Get It

Exercise capacity (EC) is a critical outcome in chronic obstructive lung disease (chronic obstructive pulmonary disease (COPD)). It measures the impact of the disease and the effect of specific interventions like pulmonary rehabilitation (PR). EC determines COPD prognosis and is associated with health-care utilization and quality of life. Field walking tests and cardiopulmonary exercise test (CPET) are two ways to measure EC. The 6-minute walking test (6MWT) is the commonest and easiest field test. CPET has the advantage of assessing maximal aerobic capacity. Determinants of EC include age, gender, breathlessness, and lung function. Previous research suggests that socioeconomic status (SES), a meaningful factor in COPD, may also be associated with EC. However, those findings have not been replicated. We aimed to determine whether SES is an independent factor associated with EC in COPD. For this analysis, we used the National Emphysema Treatment Trial (NETT) database. NETT was a multicenter clinical trial where severe COPD patients were randomized to lung volume reduction surgery or medical therapy. Measures used were taken at baseline, postrehabilitation. Patients self-reported their income and were divided in two groups whether it was less or above US$30,000. Patients with a lower income had worse results in 6MWT ( p < 0.0001). We found an independent association between income and the 6MWT in patients with severe COPD after adjusting for age, gender, lung function, dyspnea, and living conditions ( p < 0.0007). One previous publication stated the relationship between income and EC. Our research confirms and extends previous publications associating EC with income by studying a large and well characterized cohort of severe COPD patients, also addressing EC by two different methods (maximal watts and 6MWT). Our results highlight the importance of addressing social determinants of health such as income when assessing COPD patients.
Altered speech with migraine attacks: A prospective, longitudinal study of episodic migraine without aura
Peplinski, Jacob , Garcia‐Filion, Pamela , Berisha, Visar , Schwedt, Todd J. , Berisha, Visar

Mayo Clinic

Cephalalgia | November 17, 2018 | Volume: 39 | Issue: 6 | Pages: 722-731

10.1177/0333102418815505 | PMID 30449150 Get It

Background and Objective Some individuals with migraine report the presence of speech changes during their migraine attacks. The goal of this study was to compare objective features of speech during the migraine pre-attack, the migraine attack, and during the interictal period. Methods This was a prospective, longitudinal, observational study of adults with episodic migraine and healthy non-migraine controls. Participants provided speech samples three times per day using a speech elicitation tool included within a mobile app. Six complementary speech features that capture articulation and prosody were extracted from speech samples. Participants with migraine maintained a daily headache diary using the same app. A mixed effects model and t-tests were used to investigate differences in speech features between controls, the migraine pre-attack phase, the migraine attack, and the interictal period. Results In total, 56,767 speech samples were collected, including 43,102 from 15 individuals with migraine and 13,665 from matched healthy controls. Significant group-level differences in speech features were identified between those with migraine and healthy controls and within the migraine group during the pre-attack vs. attack vs. interictal periods (all p < .05). Most consistently, speech changes occurred in the speaking rate, articulation rate and precision, and phonatory duration. Within-subject analysis revealed that seven of 15 individuals with migraine showed significant change in at least one speech feature when comparing the migraine attack vs. interictal phase and four showed similar changes when comparing the pre-attack vs. interictal phases. Conclusions Changes in speech occurred in almost half of the individuals during migraine attacks. Once confirmed in subsequent studies, speech changes could be considered a feature of the migraine attack.
Testing a clinical staging model for bipolar disorder using longitudinal life chart data
Markt, Afra van der , Klumpers, Ursula M. H. , Draisma, Stasja , Dols, Annemiek , Nolen, Willem A. , Post, Robert M. , Altshuler, Lori L., Frye, Mark A. , Grunze, Heinz , Keck, Paul E., Suppes, Trisha, Beekman, Aartjan T.F. , Kupka, Ralph , van der Markt, Afra , Grunze, Heinz , McElroy, Susan L.

Mayo Clinic

Bipolar Disorders | November 17, 2018 | Volume: 21 | Issue: 3 | Pages: 228-234

10.1111/bdi.12727 | PMID 30447123 Get It

ObjectiveBipolar disorder has a wide range of clinical manifestations which may progress over time. The aim of this study was to test the applicability of a clinical staging model for bipolar disorder and to gain insight into the nature of the variables influencing progression through consecutive stages.MethodsUsing retrospectively reported longitudinal life chart data of 99 subjects from the Stanley Foundation Bipolar Network Naturalistic Follow‐up Study, the occurrence, duration and timely sequence of stages 2‐4 were determined per month. A multi‐state model was used to calculate progression rates and identify determinants of illness progression. Stages 0, 1 and several other variables were added to the multi‐state model to determine their influence on the progression rates.ResultsFive years after onset of BD (stage 2), 72% reached stage 3 (recurrent episodes) and 21% had reached stage 4 (continuous episodes), of whom 8% recovered back to stage 3. The progression from stage 2 to 3 was increased by a biphasic onset for both the depression‐mania and the mania‐depression course and by male sex.ConclusionsStaging is a useful model to determine illness progression in longitudinal life chart data. Variables influencing transition rates were successfully identified.
A treatable hypertrophic neuropathy
Pinto, Marcus Vinícius , Spinner, Robert J. , Staff, Nathan P. , Pinto, Marcus V , Staff, Nathan P

Mayo Clinic

Practical Neurology | November 17, 2018 | Volume: 19 | Issue: 1 | Pages: 80-82

10.1136/practneurol-2018-002083 | PMID 30448766 Get It

Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis
Chokesuwattanaskul, Ronpichai , Cheungpasitporn, Wisit , O’Corragain, O.A., Sharma, Konika , Preechawat, Somchai, Wijarnpreecha, Karn , Ungprasert, Patompong , Cheungpasitporn, Wisit , Chokesuwattanaskul, Ronpichai , Wijarnpreecha, Karn , Thongprayoon, Charat , Kröner, Paul T.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | November 17, 2018 | Volume: 31 | Issue: 4 | Pages: 514-519

10.1097/meg.0000000000001315 | PMID 30451705 Get It

ObjectiveThe epidemiology of atrial fibrillation (AF) in patients with cirrhosis and its clinical significance remain unclear. This study aimed (i) to investigate the pooled prevalence and/or incidence of AF in patients with cirrhosis and (ii) to assess the mortality risk of AF in patients with cirrhosis.Patients and methodsA literature search for studies that reported incidence of AF in patients with cirrhosis was carried out using Medline, Embase, and Cochrane Database from inception through July 2018. Pooled incidence with 95% confidence interval (CI) was calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018102664).ResultsSeven cohort studies including 385 866 patients with cirrhosis were identified. The pooled estimated prevalence of AF in patients with cirrhosis was 5.0% (95% CI: 2.8–8.6%). When studies that solely assessed patients undergoing transplant evaluation or on transplant waiting list were excluded, the pooled estimated prevalence of AF in patients with cirrhosis was 7.4% (95% CI: 3.5–15.2%). There was a significant association between AF and increased mortality risk in cirrhotic patients with a pooled odds ratio of 1.44 (95% CI: 1.36–1.53).ConclusionThe overall estimated prevalence of AF among patients with cirrhosis is 5.0%. Our study demonstrates a statistically significant increased mortality risk in cirrhotic patients with AF.
Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and N
Relling, Mary V. , Schwab, Matthias , Whirl‐Carrillo, Michelle , Suarez‐Kurtz, Guilherme , Pui, Ching‐Hon, Stein, Charles, Moyer, Ann M. , Evans, William E. , Klein, Teri E. , Antillon‐Klussmann, Federico Guillermo, Caudle, Kelly E. , Yeoh, Allen Eng Juh , Antillón‐Klussmann, Federico , Yang, Jun J.J. , Whirl-Carrillo, Michelle , Klein, Teri E , Yeoh, Allen E J , Pui, Ching-Hon , Kato, Motohiro , Schmiegelow, Kjeld , Schwab, Matthias

Mayo Clinic

Clinical Pharmacology & Therapeutics | November 17, 2018 | Volume: 105 | Issue: 5 | Pages: 1095-1105

10.1002/cpt.1304 | PMID 30447069 Get It

Thiopurine methyltransferase (TPMT) activity exhibits a monogenic codominant inheritance and catabolizes thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines. Loss‐of‐function alleles in the NUDT15 gene are common in Asians and Hispanics and reduce the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression. We provide recommendations for adjusting starting doses of azathioprine, mercaptopurine, and thioguanine based on TPMT and NUDT15 genotypes (updates on www.cpicpgx.org ).
The impact of adding posterior instrumentation to transpsoas lateral fusion: a systematic review and meta-analysis
Alvi, Mohammed Ali , Alkhataybeh, Redab , Wahood, Waseem , Kerezoudis, Panagiotis , Goncalves, Sandy, Murad, M. Hassan , Bydon, Mohamad , Murad, M Hassan , Alvi, Mohammed Ali

Mayo Clinic

Journal of Neurosurgery: Spine | November 16, 2018 | Volume: 30 | Issue: 2 | Pages: 211-221

10.3171/2018.7.spine18385 | PMID 30485206 Get It

OBJECTIVETranspsoas lateral interbody fusion is one of the lateral minimally invasive approaches for lumbar spine surgery. Most surgeons insert the interbody cage laterally and then insert pedicle or cortical screw and rod instrumentation posteriorly. However, standalone cages have also been used to avoid posterior instrumentation. To the best of the authors’ knowledge, the literature on comparison of the two approaches is sparse.METHODSThe authors performed a systematic review and meta-analysis of the available literature on transpsoas lateral interbody fusion by an electronic search of the PubMed, EMBASE, and Scopus databases using PRISMA guidelines. They compared patients undergoing transpsoas standalone fusion (TP) with those undergoing transpsoas fusion with posterior instrumentation (TPP).RESULTSA total of 28 studies with 1462 patients were included. Three hundred and seventy-four patients underwent TPP, and 956 patients underwent TP. The mean patient age ranged from 45.7 to 68 years in the TP group, and 50 to 67.7 years in the TPP group. The incidence of reoperation was found to be higher for TP (0.08, 95% confidence interval [CI] 0.04–0.11) compared to TPP (0.03, 95% CI 0.01–0.06; p = 0.057). Similarly, the incidence of cage movement was found to be greater in TP (0.18, 95% CI 0.10–0.26) compared to TPP (0.03, 95% CI 0.00–0.05; p < 0.001). Oswestry Disability Index (ODI) and visual analog scale (VAS) scores and postoperative transient deficits were found to be comparable between the two groups.CONCLUSIONSThese results appear to suggest that addition of posterior instrumentation to transpsoas fusion is associated with decreased reoperations and cage movements. The results of previous systematic reviews and meta-analyses should be reevaluated in light of these results, which seem to suggest that higher reoperation and subsidence rates may be due to the use of the standalone technique.